Related news from  |
Mon, 16 Nov 2026 13:23:50 +0000 |
Are Wall Street Analysts Predicting Cencora Stock Will Climb or Sink?
Cencora has lagged behind the broader market over the past year, yet analysts remain highly optimistic about the stock’s prospects.
|
Fri, 13 Nov 2026 22:14:39 +0000 |
Update: FTC Sues to Block Covetrus' $3.5 Billion Acquisition of Cencora's MWI Veterinary Supply
(Updated to add Covetrus' comment in paragraph four.) Cencora (COR), the parent company of MWI Ve
|
Fri, 13 Nov 2026 17:20:00 +0000 |
Covetrus Issues Statement on FTC Decision to Challenge Proposed Merger with MWI Animal Health
Covetrus, a leading animal health technology, product and services company, today issued the following statement in response to the Federal Trade Commission's (FTC) decision to file a lawsuit to challenge Covetrus' proposed merger with MWI Animal Health (MWI), a subsidiary of Cencora.
|
Sun, 08 Nov 2026 21:25:36 +0000 |
Cencora’s Q3 CY2026 earnings call: our top 5 analyst questions
Cencora delivered calendar Q3 2026 results that aligned with market expectations on revenue and topped analyst profit forecasts. Management credited the quarter’s performance to strong growth in specialty pharmaceuticals, driven by recent acquisitions such as OneOncology and the expansion of its management services organization (MSO) platform. CEO Bob Mauch highlighted these investments as central to Cencora’s ability to support pharmaceutical-centric care, noting increased activity in specialty
|
Thu, 05 Nov 2026 22:12:14 +0000 |
Does Earnings Beat Change The Bull Case For Cencora (COR)?
Cencora reported fiscal Q4 2026 sales of US$88.35b and net income of US$519.4m, with full year earnings rising to US$3.48b, and increased its quarterly dividend to US$0.66 per share payable on 30 November 2026. The sharp shift from a prior year quarterly net loss to profit, combined with a higher dividend and new segment reporting, gives investors clearer visibility into how specialty services and acquisitions such as OneOncology contribute to Cencora's earnings profile. Next, the focus...
|
Thu, 05 Nov 2026 21:05:39 +0000 |
Cencora Inc (COR) (Q4 2026) Earnings Call Highlights: Record Fiscal 2026 Results, New ...
Cencora Inc (COR) delivered 12% adjusted EPS growth and $3.8 billion in free cash flow for fiscal 2026 while unveiling a two-segment structure and guiding fiscal 2027 adjusted EPS to $19.40--$19.75.
|
Thu, 05 Nov 2026 07:14:18 +0000 |
What Cencora (COR) Said on Its Q4 Earnings Call
Cencora (NYSE:COR) reported higher fiscal fourth-quarter revenue and adjusted earnings as specialty drug sales and its acquisition of OneOncology contributed to growth. The company also introduced a new reporting structure that separates its specialty operations from its broader pharmaceutical distr
|
Wed, 04 Nov 2026 18:48:22 +0000 |
Cencora (COR) Q4 2026 Earnings Call Transcript
Specialty biologics now drive over half of U.S. pharmaceutical spending.
|
Wed, 04 Nov 2026 18:34:15 +0000 |
Cencora, Inc. Q4 2026 Earnings Call Summary
Moby summary of Cencora, Inc.'s Q4 2026 earnings call
|
Wed, 04 Nov 2026 17:53:00 +0000 |
Cencora Q4 Earnings & Revenues Beat on Specialty Growth, Margins Expand
COR's Q4 earnings and revenues beat estimates as specialty drug demand fuels growth and margins expand. The company raises its fiscal 2027 outlook.
|
Wed, 04 Nov 2026 13:30:06 +0000 |
Cencora (COR) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Cencora (COR) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
|
Thu, 05 Nov 2026 21:24:02 +0000 |
Drug Wholesalers Go Three-For-Three In Earnings Beats, But Only Two Stocks Pop
Drug distributors went three-for-three, with Cardinal Health putting up the last fall-quarter beat on Thursday, following the examples set by McKesson and Cencora.
|
Fri, 13 Nov 2026 23:02:02 +0000 |
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
Amgen trades at a lower forward P/E than Vertex, but Vertex's near-zero debt and cystic fibrosis dominance make the trade-off harder to call.
|
Tue, 10 Nov 2026 13:11:29 +0000 |
Can Cardinal Health Stock Repeat Its Last Five Years?
For questions about this article or underlying research, email help@trefis.com.
|
Fri, 06 Nov 2026 23:26:15 +0000 |
Is McKesson Stock Increasing Your Market Risk?
For questions about this article or underlying research, email help@trefis.com.
|
Fri, 06 Nov 2026 12:31:00 +0000 |
3 Stocks in Focus That Hiked Dividends Amid Ongoing Market Volatility
BDX, COR and UNF recently hiked dividends, offering investors steady income opportunities as market volatility, inflation and economic uncertainty persist.
|
Thu, 05 Nov 2026 21:17:27 +0000 |
The Biggest Drug Wholesaler Just Crushed Earnings Views — Here's What To Know
McKesson stock rose Thursday after the drug wholesaler topped fiscal second-quarter views and hiked its earnings guide.
|
Thu, 05 Nov 2026 16:39:19 +0000 |
What Just Happened To Medline Stock?
For questions about this article or underlying research, email help@trefis.com.
|
Thu, 05 Nov 2026 16:25:02 +0000 |
Amgen vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027?
Amgen's growth engine and Pfizer's value appeal pull in opposite directions, and the valuation gap between them is wider than many expect.
|